DK373489D0 - RECOMBINANT HYBRID PARTICLES WITH MORPHOLOGICAL PROPERTIES RESPONSIBLE FOR THE ANTI-ANGLE CASE AND INCLUDING AN IMMUNOGENIC SEQUENCE INPUTING NEUTRALIZING ANTIBODIES AGAINST ANTI-RETROVIRUS ANTIVES, OR SUCH CAN BE GIVEN - Google Patents

RECOMBINANT HYBRID PARTICLES WITH MORPHOLOGICAL PROPERTIES RESPONSIBLE FOR THE ANTI-ANGLE CASE AND INCLUDING AN IMMUNOGENIC SEQUENCE INPUTING NEUTRALIZING ANTIBODIES AGAINST ANTI-RETROVIRUS ANTIVES, OR SUCH CAN BE GIVEN

Info

Publication number
DK373489D0
DK373489D0 DK373489A DK373489A DK373489D0 DK 373489 D0 DK373489 D0 DK 373489D0 DK 373489 A DK373489 A DK 373489A DK 373489 A DK373489 A DK 373489A DK 373489 D0 DK373489 D0 DK 373489D0
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
retrovirus
antives
inputing
Prior art date
Application number
DK373489A
Other languages
Danish (da)
Other versions
DK373489A (en
Inventor
Pierre Tiollais
Marie-Louise Michel
Maryline Mancini
Eliane Sobczak
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of DK373489D0 publication Critical patent/DK373489D0/en
Publication of DK373489A publication Critical patent/DK373489A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The invention relates to an active principle of a vaccine against HIV. This active principle consists of recombinant particles exhibiting the essential morphological characteristics of HBsAg particles and comprising, flush with the surface of these particles, the essence of the amino acid sequence (S) coded by the S region and, if appropriate, all or part of the amino acid sequence coded by the pre-S region of the genome of the hepatitis B virus, upstream of the said amino acid sequence (S), these recombinant particles being characterised in that they additionally comprise an immunogenic amino acid sequence inducing antibodies which are neutralising in respect of a retrovirus of the HIV class or capable of being recognised by such antibodies, this sequence itself comprising at least one epitope capable of being recognised by the B lymphocytes, and at least one epitope capable of being recognised by the T lymphocytes and, where appropriate, at least one site of attachment to the CD4 receptor of human T4 lymphocytes, this immunogenic sequence being either inserted in the pre-S amino acid sequence or wholly or partly substituted with the pre-S protein.
DK373489A 1988-07-29 1989-07-28 RECOMBINANT HYBRID PARTICLES WITH MORPHOLOGICAL PROPERTIES RESPONSIBLE FOR THE ANTI-ANGLE CASE AND INCLUDING AN IMMUNOGENIC SEQUENCE INPUTING NEUTRALIZING ANTIBODIES AGAINST ANTI-RETROVIRUS ANTIVES, OR SUCH CAN BE GIVEN DK373489A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8810336A FR2635532B1 (en) 1988-07-29 1988-07-29 HYBRID RECOMBINANT HBSAG PARTICLES: MORPHOLOGICAL CHARACTERISTICS OF THE HBSAG ANTIGEN CONTAINING 1 IMMUNOGENIC SEQUENCE INDUCING NEUTRALIZING ANTIBODIES DIRECTED AGAINST HIV OR LIKELY TO BE RECOGNIZED BY SUCH ANTIBODIES; NUCLEOTIDE SEQUENCES ENCODING FOR SUCH PARTICLES; VACCINES CONTAINING THEM

Publications (2)

Publication Number Publication Date
DK373489D0 true DK373489D0 (en) 1989-07-28
DK373489A DK373489A (en) 1990-01-30

Family

ID=9368968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK373489A DK373489A (en) 1988-07-29 1989-07-28 RECOMBINANT HYBRID PARTICLES WITH MORPHOLOGICAL PROPERTIES RESPONSIBLE FOR THE ANTI-ANGLE CASE AND INCLUDING AN IMMUNOGENIC SEQUENCE INPUTING NEUTRALIZING ANTIBODIES AGAINST ANTI-RETROVIRUS ANTIVES, OR SUCH CAN BE GIVEN

Country Status (7)

Country Link
EP (1) EP0354109B1 (en)
JP (1) JPH02211881A (en)
AT (1) ATE136933T1 (en)
DE (1) DE68926274D1 (en)
DK (1) DK373489A (en)
FR (1) FR2635532B1 (en)
PT (1) PT91316B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421626A1 (en) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
CA2085084A1 (en) * 1991-12-18 1993-06-19 John Hannah Synthetic peptides comprising a cyclic hiv principal neutralizing determinant and a t-cell stimulatory epitope
AU3269793A (en) * 1991-12-27 1993-07-28 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it
JPH07505412A (en) * 1992-04-14 1995-06-15 ブリティッシュ　バイオテック　ファーマシューティカルズリミテッド Induction of CTL responses
IT1256575B (en) * 1992-12-10 1995-12-11 Cesalpino Andrea Fond PROCEDURE FOR THE PREPARATION OF IMMUNOGENS CONSTITUTED BY EXOGENOUS ANTIGENS CAPABLE OF GENERATING NOT ONLY THE IMMUNE RESPONSE OF T HELPER LYMPHOCYTES, BUT ALSO AN EFFECTIVE RESPONSE OF CYTOTOXIC T LYMPHOCYTES; AND IMMUNOGENES SO OBTAINABLE.
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
EP1837017A3 (en) * 1997-01-22 2009-12-23 Eisai Inc. Microparticles for delivery of nucleic acid
FR2844514B1 (en) 2002-09-16 2007-10-19 Neovacs STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES, COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0038765B1 (en) * 1980-04-22 1987-09-02 Institut Pasteur Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
FR2581394B1 (en) * 1985-05-02 1988-08-05 Grp Genie Genetique PARTICLES HAVING IMMUNOGENIC PROPERTIES OF THE HBS ANTIGEN AND CARRYING A FOREIGN ANTIGENIC SITE TO THE EPITOPES CARRIED BY THE HBS ANTIGEN, ANIMAL VECTORS AND CELLS FOR THE PRODUCTION OF SUCH PARTICLES AND COMPOSITIONS CONTAINING SUCH PARTICLES FOR THE PRODUCTION
EP0269520A3 (en) * 1986-11-21 1988-08-24 Institut Pasteur Retrovirus of the type hiv-2, susceptible to provoke aids, and its antigenic and nucleic-acid constituents
ES2104556T3 (en) * 1987-01-16 1997-10-16 Pasteur Institut PEPTIDES THAT HAVE IMMUNOLOGICAL PROPERTIES OF HIV-2.
EP0278940A3 (en) * 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis b virus surface antigens and hybrid antigens containing them

Also Published As

Publication number Publication date
DE68926274D1 (en) 1996-05-23
PT91316B (en) 1995-08-09
EP0354109A1 (en) 1990-02-07
ATE136933T1 (en) 1996-05-15
DK373489A (en) 1990-01-30
JPH02211881A (en) 1990-08-23
FR2635532B1 (en) 1992-05-22
EP0354109B1 (en) 1996-04-17
FR2635532A1 (en) 1990-02-23
PT91316A (en) 1990-02-08

Similar Documents

Publication Publication Date Title
ATE97164T1 (en) RECOMBINANT VACCINIA VIRUS MVA.
EE200100292A (en) HBV core antigenic particles with multiple immunogenic components that attach to peptide ligands
DK513388D0 (en) PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT
DK0725824T3 (en) Immunodominant human T cell epitopes of hepatitis C virus
FI935808A (en) Hepatitis C virus (HCV) polypeptide
EP0278940A3 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
DE3852221T2 (en) Animal cell with antigenic protein introduced therein.
DE68927025T2 (en) HIV-2 virus variants
DK0588578T3 (en) immunogens
DK0726758T3 (en) Peptides to induce cytotoxic T-lymphocyte responses to hepaptitis B virus
DK373489A (en) RECOMBINANT HYBRID PARTICLES WITH MORPHOLOGICAL PROPERTIES RESPONSIBLE FOR THE ANTI-ANGLE CASE AND INCLUDING AN IMMUNOGENIC SEQUENCE INPUTING NEUTRALIZING ANTIBODIES AGAINST ANTI-RETROVIRUS ANTIVES, OR SUCH CAN BE GIVEN
DE69434954D1 (en) Peptides for inducing a response of the cytotoxic T lymphocytes directed against the hepatitis B virus
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
CA2057828A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ES2062990T3 (en) VACCINES, WHICH CONTAIN PROTEIN F FROM AIDS VIRUSES.
GB9925966D0 (en) Threapeutic vaccines against variable viruses and other targets
DK204588A (en) HUMAN RHINOVIRUS PEPTIDES, PROCEDURES FOR THEIR PREPARATION AND VACCINES CONTAINING SUCH PEPTIDES
ATE128733T1 (en) MONOCLONAL ANTIBODIES AGAINST HIV GP120.
ATE143373T1 (en) PROTEINS, VACCINES AND NUCLIC ACIDS
DK284389A (en) PRECURSOR ANTIGENES
DK123288D0 (en) PROCEDURE FOR INHIBITING RECOMBINANT HEPATITIS B THE SURFACE ANTI

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment